Compare Gilead Sciences, Inc. (GILD) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares Global Clean Energy ETF — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while iShares Global Clean Energy ETF trades at $17.23 (market cap $2.27B). The key difference: Gilead Sciences, Inc. is far larger — about 80.4× iShares Global Clean Energy ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and iShares Global Clean Energy ETF for 87 Days on average.
| GILD | ICLN | |
|---|---|---|
Market Cap | $182.40B | $2.27B |
Volume | 4,469,821 | 6,845,064 |
Sector | Health | — |
52-Week High | $155.80 | $23.75 |
52-Week Low | $116.74 | $15.78 |
Typical Hold Time | 111 Days | 87 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
ICLN trades at $17.31, down 1.31% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF's financial ratios are unavailable in the provided data, but recent news highlights its focus on global clean energy with 105 holdings and a 0.38% expense ratio. It faces volatility, with a 57.2% maximum drawdown noted in comparisons against traditional energy ETFs.
The outlook for ICLN is mixed; geopolitical tensions and global renewable energy investments provide tailwinds, but high volatility and competition from fossil fuel ETFs pose risks. Investors should weigh its growth potential against expense ratios and performance consistency in the evolving energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
